Trial Profile
Randomized Phase 2 Clinical Trial of Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab + Neoantigen Vaccine Vs. Nab-Paclitaxel + Durvalumab (MEDI4736) + Tremelimumab in Patients With Metastatic Triple Negative Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Durvalumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary) ; Peptide vaccines (Primary) ; Poly ICLC (Primary) ; Tremelimumab (Primary)
- Indications Advanced breast cancer; Male breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 24 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2024.
- 24 Dec 2022 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2024.
- 07 Jan 2022 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.